Targeting of erbB3 receptor to overcome resistance in cancer treatment
about
Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future PerspectivesGene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsBreast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation.ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Evaluation of Biomarkers for HER3-targeted Therapies in Cancer.Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical RoleAffibody-mediated PET imaging of HER3 expression in malignant tumours.Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 PhosphorylationCharacterization of a P-Rex1 gene signature in breast cancer cellsTargeted therapies in breast cancer: New challenges to fight against resistance.HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600ERandomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.Type 1 Diabetes Candidate Genes Linked to Pancreatic Islet Cell Inflammation and Beta-Cell Apoptosis.EGFR Family Members' Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer.HER3 expression is correlated to distally located and low-grade colon cancer.ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis.HER-3: hub for escape mechanisms.MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma.89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma.Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.A comparative study of synthetic and semisynthetic approaches for ligating the epidermal growth factor to a bivalent scaffold.Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).Prognostic significance of the expression of HER family members in primary osteosarcoma.Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
P2860
Q26772042-7E4E9EA0-F29E-473C-92F2-EBA4363699F7Q27853108-777A3A5B-B994-49F6-9552-FBB55025B580Q28086768-D817E3C2-AEA7-4B10-9078-FA76FAE42F3EQ30238959-EB402E07-645C-4932-8781-5CA33C286CA1Q33597555-EC713AA3-F19B-40E9-8DD3-7EE9052EBB8BQ33772914-4A774FD6-9554-4567-8359-26567A3CAACDQ34506951-835222A2-C0F5-437C-A0C7-95921892DB67Q34704781-833AEC23-7E8E-411D-B6BC-B7B7295F6A64Q35174240-3A668D55-9D89-46DC-91BC-FE03AB1440DBQ35682599-3BE025D2-A022-4E69-B368-D0B1FC28A611Q35793986-E6D020B9-FD56-4837-A001-FD7B2F4A425AQ35842236-9479CEB3-0DDF-4D19-893F-13CDEF36B654Q36174716-9DB16559-95D4-44ED-A4CA-27F18F00B6C3Q37109776-84B55401-E029-4DAD-A24F-4B005C246C0DQ37190106-38DB620D-5840-4497-845B-C8FC5F481103Q37243523-C4D57496-5026-48E7-8066-85D11B861451Q37588287-3D3DED2E-FABF-4E1D-AAE6-B518C592E6D2Q37743048-717C69BE-31EC-4A71-A91A-009F4C744096Q37746163-24730F90-C5C3-4DCC-8E8B-A05A8331F5B4Q38376696-31339E25-9A1E-4FD5-80A7-66E98D9B7779Q38514601-2710CA75-9502-41F0-BA5A-352151B3021AQ38623361-D3970906-692E-474B-9DE4-84CE3985C92DQ38770505-45CF9170-0B8B-4469-9B48-6E7ECCF4E8CDQ38849622-F4336B75-4968-4C78-B561-73F6B401F912Q39140831-8B95D255-55BA-4101-80E4-F7238FE75850Q39198504-D226088B-E391-4B50-A78D-BDF75D8270DCQ40918277-A58184EA-9BE8-45EA-B1AB-4AB31375184CQ41058774-CB4FB3B3-52BA-436B-9F8A-5DF04CC4166EQ41135979-5792D98B-CE88-4CA0-8274-0AB373A58CBFQ41583353-D4F91221-F7AC-4B8F-8916-DBEBC920C03EQ41821510-4C32EDCB-998C-4D52-BC6A-54B0C7542259Q43992554-54FA7685-27D1-42C3-96B0-C2E34ED77866Q45959066-C5DD8166-4297-4D9B-AFF2-C7979772EFB6Q47150730-99F44AB9-F027-4F6F-A187-EA6A4A55BDC5Q47203450-79B1EBC3-BCE9-408C-A6CB-3DE747A0711FQ47438485-8824ADC5-EEFA-49C7-AD95-017B161EF99AQ48128794-EA86FCE3-F04D-43D3-A4D4-79FF02BEFFBAQ55384914-F47D67EA-7FBE-487E-898C-FD16D91B3497Q55710586-4CAE8EA4-089D-4599-85EB-174B7AC572B9Q58796351-E7B7E261-99F3-4972-B428-427EFF66F444
P2860
Targeting of erbB3 receptor to overcome resistance in cancer treatment
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@ast
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@en
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@nl
type
label
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@ast
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@en
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@nl
prefLabel
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@ast
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@en
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Targeting of erbB3 receptor to overcome resistance in cancer treatment
@en
P2093
P2860
P2888
P3181
P356
10.1186/1476-4598-13-105
P407
P50
P5008
P577
2014-05-08T00:00:00Z
P5875
P6179
1038022962